FDA — authorised 28 June 1974
- Application: NDA016998
- Marketing authorisation holder: PARKE DAVIS
- Local brand name: UTICORT
- Indication: CREAM — TOPICAL
- Status: approved
🇺🇸 Betamethasone 17-Benzoate in United States
FDA authorised Betamethasone 17-Benzoate on 28 June 1974
Marketing authorisations
FDA
- Status: approved
FDA
- Application: NDA017528
- Marketing authorisation holder: PARKE DAVIS
- Local brand name: UTICORT
- Indication: LOTION — TOPICAL
- Status: approved
FDA
- Application: NDA017244
- Marketing authorisation holder: PARKE DAVIS
- Local brand name: UTICORT
- Indication: GEL — TOPICAL
- Status: approved
FDA
- Application: NDA018089
- Marketing authorisation holder: PARKE DAVIS
- Local brand name: UTICORT
- Indication: OINTMENT — TOPICAL
- Status: approved
Betamethasone 17-Benzoate in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Betamethasone 17-Benzoate approved in United States?
Yes. FDA authorised it on 28 June 1974; FDA has authorised it; FDA has authorised it.
Who is the marketing authorisation holder for Betamethasone 17-Benzoate in United States?
PARKE DAVIS holds the US marketing authorisation.